Pfizer to sell Chinese biologics manufacturing facility to WuXi
Multinational makes ‘difficult decision’ to halt presence in Chinese biosimilars market five years after $350 million investment
Pfizer has agreed to sell its single-use biologics manufacturing plant in Hangzhou, eastern China to Chinese contract development and manufacturing organisation, WuXi Biologics, five years after investing $350 million to build the facility.
The sale of the 50,000 sq m facility, which has been operational since 2018, effectively ends Pfizer’s involvement in the Chinese biosimilars market. Pfizer had originally planned to manufacture three biosimilars for the Chinese market.
The transaction is expected to close in the first half of 2021 and financial details have not been disclosed.
“After a comprehensive review of the biosimilars market and the company’s global manufacturing network, Pfizer has made a difficult decision to halt its biosimilars programs in China and to sell 100% of its equity interest in Pfizer Biologics (Hangzhou) Co. Ltd,” Pfizer said in a statement sent to CPHI Online.
“This transaction notwithstanding, Pfizer remains committed to continue to realize its purpose – breakthroughs that change patients’ lives in China,” the company added.
In a statement, Wuxi Biologics said the addition of Hangzhou and its entire labour force would boost its drug substance and drug product capacities to “address surging manufacturing demands” and that production would start shortly after the closure of the deal.
The Hangzhou plant includes drug substance capacities equipped with two 2000L single-use bioreactors expandable to 4x2000L and drug product capacities of vial filling and pre-filled syringe.
“Globally DS and especially DP capacities are in urgent need now,” said Dr. Chris Chen, CEO of WuXi Biologics. “The acquisition will allow us to better enable our global partners to develop and manufacture premier-quality biologics to benefit patients around the world.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance